Protagen AG, Dortmund, and Kairos GmbH, Bochum, a specialist in IT solutions for biobank management announced today a marketing & sales cooperation. Both companies are planning for a long term partnership in which Protagen will profit from the competence in highly efficient administration and documentation of thousands of patient samples. In return, Protagen will actively present and demonstrate the expertise of Kairos to the market.
"Protagen has established an industrial standard for automated highthroughput expression of recombinant human proteins and their respective use for biomarker development and clinical validation. In addition, we have built an excellent and unique network of internationally renowned clinical partners in all relevant indication areas", explains Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics at Protagen. "The expertise of Kairos will complement our technology position. In addition, it will support our collaborations with drug development companies in a very efficient way and will allow for more effective project and study management."
Martin Zünkeler, founder and General Manager of Kairos adds "Decisive for the partnership with Protagen was the high grade of automation established in the labs, and the overall high quality of the processes employed. For instance, the fully automated aliquotation with latest robotic systems is already daily routine at Protagen. By and large, this is an ideal situation to adapt and develop software solutions for study management and biobanking".
About Kairos
The Kairos GmbH is a renowned IT specialist, which can look back at over ten years of experience of developing IT-system solutions for the healthcare sector. In addition to an advanced technological knowledge regarding the implementation of medical middleware platforms, Kairos has a comprehensive know-how of the ITsupported orchestration of work processes using workflow engines. Currently Kairos is developing and marketing a portal for the organization and coordination of crosssection centers in oncology (Comprehensive Cancer Center) as well as a biobank system, which allows for a longitudinal classification of sample data in clinical contexts. Kairos' second main focus is to participate in research projects in the sector of biomedicine. To this effect, Kairos is in the process of realizing a new system with a study editor, in the ForSaTum project. This system warrants the quality-assured implementation of preclinical studies in accordance with the SOPs.
"Protagen has established an industrial standard for automated highthroughput expression of recombinant human proteins and their respective use for biomarker development and clinical validation. In addition, we have built an excellent and unique network of internationally renowned clinical partners in all relevant indication areas", explains Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics at Protagen. "The expertise of Kairos will complement our technology position. In addition, it will support our collaborations with drug development companies in a very efficient way and will allow for more effective project and study management."
Martin Zünkeler, founder and General Manager of Kairos adds "Decisive for the partnership with Protagen was the high grade of automation established in the labs, and the overall high quality of the processes employed. For instance, the fully automated aliquotation with latest robotic systems is already daily routine at Protagen. By and large, this is an ideal situation to adapt and develop software solutions for study management and biobanking".
About Kairos
The Kairos GmbH is a renowned IT specialist, which can look back at over ten years of experience of developing IT-system solutions for the healthcare sector. In addition to an advanced technological knowledge regarding the implementation of medical middleware platforms, Kairos has a comprehensive know-how of the ITsupported orchestration of work processes using workflow engines. Currently Kairos is developing and marketing a portal for the organization and coordination of crosssection centers in oncology (Comprehensive Cancer Center) as well as a biobank system, which allows for a longitudinal classification of sample data in clinical contexts. Kairos' second main focus is to participate in research projects in the sector of biomedicine. To this effect, Kairos is in the process of realizing a new system with a study editor, in the ForSaTum project. This system warrants the quality-assured implementation of preclinical studies in accordance with the SOPs.
